Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Expected to Announce Quarterly Sales of $850,000.00

Analysts forecast that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will post $850,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.50 million and the lowest estimate coming in at $200,000.00. Infinity Pharmaceuticals posted sales of $22.00 million during the same quarter last year, which suggests a negative year-over-year growth rate of 96.1%. The company is scheduled to announce its next earnings results on Monday, November 4th.

According to Zacks, analysts expect that Infinity Pharmaceuticals will report full-year sales of $3.93 million for the current financial year, with estimates ranging from $2.00 million to $7.00 million. For the next year, analysts expect that the firm will post sales of $800,000.00. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.03). The firm had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $2.60 million. Infinity Pharmaceuticals had a negative return on equity of 42.16% and a negative net margin of 77.80%.

A number of research analysts have commented on the stock. ValuEngine upgraded shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. CIBC assumed coverage on shares of Infinity Pharmaceuticals in a report on Thursday, June 27th. They set an “outperform” rating on the stock. Finally, Oppenheimer assumed coverage on shares of Infinity Pharmaceuticals in a report on Thursday, June 27th. They set an “outperform” rating and a $3.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. Infinity Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $2.67.

A number of hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its holdings in Infinity Pharmaceuticals by 12.4% during the second quarter. Renaissance Technologies LLC now owns 1,002,006 shares of the biotechnology company’s stock worth $1,804,000 after buying an additional 110,806 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Infinity Pharmaceuticals by 10.9% in the second quarter. Acadian Asset Management LLC now owns 601,517 shares of the biotechnology company’s stock valued at $1,083,000 after purchasing an additional 58,998 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Infinity Pharmaceuticals by 5.0% in the second quarter. Jacobs Levy Equity Management Inc. now owns 201,438 shares of the biotechnology company’s stock valued at $363,000 after purchasing an additional 9,511 shares in the last quarter. Evercore Wealth Management LLC lifted its holdings in shares of Infinity Pharmaceuticals by 20.7% in the second quarter. Evercore Wealth Management LLC now owns 143,138 shares of the biotechnology company’s stock valued at $258,000 after purchasing an additional 24,553 shares in the last quarter. Finally, Athanor Capital LP purchased a new stake in shares of Infinity Pharmaceuticals in the second quarter valued at about $177,000. 53.84% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:INFI traded down $0.04 during midday trading on Friday, hitting $1.12. 34,369 shares of the company were exchanged, compared to its average volume of 143,368. The company has a fifty day simple moving average of $1.14 and a 200 day simple moving average of $1.45. Infinity Pharmaceuticals has a fifty-two week low of $0.96 and a fifty-two week high of $2.68. The company has a current ratio of 7.93, a quick ratio of 7.93 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $66.45 million, a PE ratio of -5.60 and a beta of 1.82.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Further Reading: What are popular range trading strategies?

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.